Pfizer
Pfizer's Beqvez Bests Standard Hemophilia B Care in Trial, but Unclear Why Not All Sustain Benefits
Premium
Patients had fewer bleeds after treatment with Beqvez compared to standard treatment, but questions remain about which patients have enduring benefits.
A study presented at the ESMO Congress shed light on an ADC directed against an immune checkpoint in PD-L1-expressing solid cancers.
Braftovi, Mektovi Approved in Europe for BRAF V600E-Mutant NSCLC
A Phase II trial of the combo demonstrated response rates of 75 percent and 46 percent in treatment-naïve and previously treated NSCLC patients, respectively.
Flagship Pioneering, Quotient Therapeutics Team up for Pfizer Drug Discovery Partnership
Under the agreement, the companies aim to discover new drug targets in cardiovascular and renal diseases using Quotient's cell phenotyping and genomic sequencing platform.
Pfizer Oncology Product Revenues Jump 26 Percent in Q2
The firm reported $845 million in Q2 revenue from oncology products gained in its acquisition of Seagen last year.